graph Evidence gap map comparisons
atezolizumab based treatment
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
es-BC - TNBC - NA - all population 5   
Comparator:  vs placebo plus SoC; 
Risk of bias:  low;   some concerns;   high;  NA;